Clinical trial NCT05509374: Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
Official title: Phase II, Single-arm Trial of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Multiple Myeloma
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2022-08-22
Enrollment: 33
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the evaluate the efficacy and safety of administering a combination of carfilzomib, pomalidomide, and dexamethasone in patients with relapsed or advanced multiple myeloma after carfilzomib, lenalidomide, and dexamethasone therapy.

Detailed description: This study is a phase 2 study in which patients with RRMM under 80 years of age who have been treated with lenalidomide monotherapy for at least 6 months after KRd combination therapy will receive carfilzomib, pomalidomide, and dexamethasone combination therapy.

A total of 33 participants are recruited.

KPd will be administered until progressive disease or unacceptable toxicities.

Participants who discontinued treatment will be followed up for disease status and survival at 2-month intervals.

Responses are assessed using the International Myeloma Working Group (IMWG) response criteria and the safety profile is described using NCI-CTCAE v5.0.

Eligibility criteria: Inclusion Criteria:

1. Age from 20 to 80 years-old
2. Relapse or progression of multiple myeloma after treatment of carfilzomib/lenalidomide/dexamethasone (KRd)
3. KRd treatment 12 cycles or more and lenalidomide maintenance for at least 6 months or KRd 4-6 cycles followed by ASCT and lenalidomide maintenance for at least 6 months
4. Measurable disease

   * Serum M-protein ≥ 1 g/dL (10 g/L)
   * Urine M-protein ≥ 200 mg/24 hr
   * Serum FLC assay: difference of FLC ≥ 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal (KL ratio \< 0.26 or \> 1.65) if Serum EP or urine EP is not measurable
5. Adequate organ functions

   * Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L
   * Platelets ≥ 50 x 109/L (≥ 30 x 109/L if myeloma involvement is \> 50% in the bone marrow)
   * Hemoglobin ≥ 8.0 g/dL
   * Creatinine clearance ≥ 30 mL/minute or Serum Cr \<3.0 g/dL
   * Serum Bilirubin ≤ 1.5 x ULN
   * AST and ALT ≤ 3 x ULN
6. Eastern Cooperative Oncology Group performance scale 0\~2
7. Life expectancy longer than 3 months
8. Written informed consent
9. Prior therapy with bortezomib
10. Patients who meet the following criteria

    * If a woman of childbearing age

      * Women who are willing to use two reliable methods of contraception from 4 weeks prior to administration of study drug, while receiving, temporarily suspending administration, and 4 weeks after administration of the study drug.
      * Women who have a negative pregnancy test with a minimum sensitivity of 25 IU/mL under medical management
    * For men Men who agree to abstain from absolute abstinence or use a proper method of contraception for the entire duration of treatment and 28 days after the last dose

      * Women of childbearing age Women who have not undergone hysterectomy or bilateral oophorectomy, women who have not undergone spontaneous menopause for at least 24 consecutive months (i.e., menstruate at any time during the last 24 months. However, amenorrhea after chemotherapy does not exclude the possibility of pregnancy).
      * Proper method of contraception
    * Very effective way Intrauterine device, hormone therapy (hormone implant, intrauterine system releasing levonorgestrel, medroxyprogesterone acetate depot injection, tablets containing progesterone to inhibit ovulation), tubal ligation, varicose veins in men
    * Effective way Men's condom use, diaphragm method, cervical cap

Exclusion Criteria:

1. Grade 3\~4 non-hematologic toxicity by carfilzomib during the previous carfilzomib treatment
2. Prior therapy with pomalidomide
3. Hypersensitivity to thalidomide or lenalidomide
4. Previous refractoriness to carfilzomib according to the IMWG criteria
5. Myocardial infarct within 6 months, heart failure of NYHA Class III\~IV, uncontrolled ventricular arrhythmia, severe coronary arterial obstructive disease
6. Active infection with 14 days prior to treatment
7. Uncontrolled hypertension (Defined as an average systolic blood pressure \>= 160 mmHg or diastolic \>= 100 mmHg) or diabetes (HbA1c \> 7.0%)
8. HIV, HBV, HCV infection (exception if adequately controlled HBV (undetectable HBV DNA (\< 20 IU/mL or concurrent use of an anti-viral agent), HCV)
9. Severe or uncontrolled medical conditions, laboratory abnormalities, or psychiatric disorders that may preclude the participation of the study by the physician's discretion
10. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment
11. Diagnosis of other malignant disease other than myeloma within 5 year. Exceptions are properly treated non-melanomatous skin cancers, cervical intraepithelial neoplasia, prostate cancer that do not require treatment, or properly excised well-differentiated thyroid cancers.
12. Pregnant or nursing women
13. Waldenstroem's macroglobulinemia, POEMS syndrome, or plasma cell leukemia, light chain amyloidosis
14. LV ejection fraction \< 40%

Primary outcomes:
measure: Overall response rate
timeFrame: assessed for approximately 3 years after administration
Secondary outcomes:
measure: Complete response rate
timeFrame: assessed for approximately 3 years after administration
measure: Progression free survival rate
timeFrame: assessed for approximately 3 years after administration
measure: Overall survival
timeFrame: assessed for approximately 3 years after administration
measure: Duration of response
timeFrame: assessed for approximately 3 years after administration
measure: Time to response
timeFrame: assessed for approximately 3 years after administration
measure: Incidence of treatment-emergent adverse events
timeFrame: assessed for approximately 3 years after administration
measure: Minimal residual disease negativity
timeFrame: up to 3 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Kihyun Kim, Ph.D
role: PRINCIPAL_INVESTIGATOR
References: